Oxford Biomedica plc announced that it has expanded its License and Supply Agreement ("LSA") with Cabaletta Bio, Inc. ("Cabaletta Bio"), a Philadelphia-based clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases. This follows on from the LSA announced in January 2022 and adds CD19 as a new target. Oxford Biomedica initially licensed its LentiVector®?

platform to Cabaletta Bio for their lead product candidate, DSG3-CAART. The agreement has now been extended to grant a non-exclusive license to Cabaletta under Oxford Biomedica's LentiVector®? platform IP for their CAR-T programme, CABA-201, a 4-1BB-containing fully human CD19-CAR T cell investigational therapy.

Cabaletta Bio has received two IND clearances to date for CABA-201 and plans to initiate a Phase 1/2 clinical trial for patients with systemic lupus erythematosus and lupus nephritis and a separate Phase 1/2 clinical trials for patients with myositis. Under the terms of the expanded agreement, Oxford Biomedica will receive an undisclosed upfront payment, as well as additional payments relating to the development and manufacture of lentiviral vectors for use in clinical trials. The Company will also receive certain development and regulatory milestone payments and an undisclosed royalty on net sales of products that utilise the Company's LentiVector® platforms.